Frédéric Bigot

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini et al. · European Journal of Cancer · 2017 · 215 citations

Prognostic Evaluation, Autoimmune Disease, Immunotherapy Phase +10

Risk factors for de Quervain’s disease in a French working population

Audrey Petit Le Manac’h, Yves Roquelaure, Catherine Ha et al. · Scandinavian Journal of Work Environment & Health · 2011 · 71 citations · Full text

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

D. Debieuvre, Olivier Molinier, L. Falchero et al. · The Lancet Regional Health - Europe · 2022 · 68 citations · Full text

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma

Nicolas Pécuchet, Frédéric Bigot, Julie Gachet et al. · Annals of Oncology · 2013 · 63 citations

Triple Combination, Genitourinary Cancer, Duct Carcinoma +7

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Alwin Krämer, Tilmann Bochtler, Chantal Pauli et al. · The Lancet · 2024 · 58 citations · Full text

Therapy Versus Chemotherapy, Health Sciences, Medicine +11